Total raised
$124.0M
Last: Series D 2020-07
Stage
—
Founded
2010
Headcount
—
HQ
Tel Aviv, Israel
Sector
—
About
Sight Diagnostics developed advanced blood diagnostics platforms utilizing computer vision and machine learning. Its flagship product, Sight OLO, is an FDA-cleared and CE-marked analyzer that performs complete blood count (CBC) tests from a finger-prick or venous sample, delivering lab-grade results in minutes. The company's technology was initially deployed for malaria detection with its Parasight platform and expanded to provide rapid diagnostics for various blood conditions, aiming to decentralize and improve access to blood testing. After raising approximately $124 million, the company laid off all its employees in April 2026 and is on the brink of closure.
Funding history · 5 rounds · $124.0M total
2020-07
Series D
$71.0M
2019-02
Series C
$27.8M
2016-08
Series B
$15.8M
2014-04
Series A
$6.0M
2011-08
Seed
$3.2M
Team · 2
Daniel Levner
Founder ·
Yossi Pollak
Founder ·
Sectors & technology
Technologies
Target customers
Business model
B2B
Highlights
undefined Patents
Tags
blood-testmedical-devicesdiagnosticsreal-timecomputer-visioninfectious-diseasehematologybioinformaticsartificial-intelligencemedical-technologiespediatricsoncologydata-analyticsinfectionhospitalsdigital-healthcaremachine-learningdetectiondoctorsimage-processingclinicslaboratories